 Silence Therapeutics PLC LON:SLN, NASDAQ:SLN has reported positive safety data from a phase I trial of its lead asset. SLN124, which is being developed to treat iron-loading anaemia conditions such as thalassemia and myelodysplastic syndrome MDS, was also shown to be effective in reducing plasma iron levels and had a long duration of action. 